Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-.kappa.B activation inhibitor capable of blocking the activation of NF-.kappa.B.